<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1804245173
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Fibrosta
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIROFIBAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µ/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C Don't Freez
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        753.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fibrosta is used to help assist the blood flow to your heart and to help prevent chest pain and heart attacks. It works by preventing platelets, cells found in the blood, from forming blood clots.&nbsp;</p><p>This medicine may also be used in patients whose heart vessels are dilated with a balloon (percutaneous coronary intervention or PCI). This is a procedure, possibly with implantation of a small tube (stent), to improve the blood flow to the heart.&nbsp;</p><p>Fibrosta is intended for use with aspirin and unfractionated heparin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Fibrosta </strong></p><ul><li>If you are allergic (hypersensitive) to tirofiban or any of the other ingredients of Fibrosta (listed in Section 6 &ldquo;What Fibrosta contains&rdquo;).</li><li>If you are bleeding internally or have a history of bleeding internally within the last 30 days.</li><li>If you have a history of bleeding in the brain, brain tumor or abnormal blood vessels in the brain.</li><li>If you have severe uncontrolled high blood pressure (malignant hypertension).</li><li>If you have a low blood platelet count (thrombocytopenia) or problems with blood clotting.</li><li>If you developed thrombocytopenia if you had received treatment with Fibrosta or another medicine in the same group of drugs previously.</li><li>If you have a history of stroke within the last 30 days or any history of stroke with bleeding.</li><li>If you have been seriously injured or had a major operation within the last 6 weeks.</li><li>If you have severe liver disease.</li></ul><p>Your doctor will review your medical history to see if you are at an increased risk of any side effects associated with being given this medicine.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor before using Fibrosta, if you have or have had:</p><ul><li>Any medical problems</li><li>Any allergies</li><li>Cardiopulmonary resuscitation (CPR), a biopsy, or a procedure to break up kidney stones within the last 2 weeks</li><li>Been seriously injured or had a major operation within the last 3 months</li><li>An ulcer in the stomach or intestine (duodenum) within the last 3 months</li><li>A recent bleeding disorder (within 1 year) such as bleeding in the stomach or intestine, or blood in your urine or stool</li><li>Recent spinal procedure</li><li>A history or symptoms of splitting of the aorta (aortic dissection)</li><li>Uncontrolled high blood pressure (hypertension)</li><li>An inflammation of the lining around your heart (pericarditis)</li><li>An inflammation of the blood vessels (vasculitis)</li><li>Problems with the blood vessels in the back of your eye (retina)</li><li>Treatment with medications that help to prevent or dissolve blood clots</li><li>Kidney problems</li><li>A special intravenous line inserted under your collar bone within the last 24 hours</li><li>Heart failure</li><li>Very low blood pressure due to a failing heart (cardiogenic shock)</li><li>A liver disorder</li><li>Low blood count or anemia</li></ul><p><strong>Other medicines and Fibrosta</strong><br />In general, tirofiban can be used with other medicines. Please tell your doctor if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription, as some drugs may affect each other&#39;s action. It is especially important to tell your doctor if you are taking other medicines that help prevent your blood from clotting such as warfarin.</p><p><strong>Fibrosta with food and drink</strong><br />Food and drink have no effect on this medicine.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p><strong>Driving and using machines</strong><br />Due to your disease state, you will not be able to drive or operate machinery while Fibrosta is being used.</p><p><strong>Fibrosta contains sodium</strong><br />Fibrosta contains sodium. This medicine contains 189 mg sodium (main component of cooking/table salt) in each 50 ml. This is equivalent to 9.45% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fibrosta should be prescribed by a qualified doctor who is experienced in the management of heart attacks.</p><p>You have been given, or are about to be given, Fibrosta into a vein. Your doctor will decide on the appropriate dose, depending on your condition and your weight.</p><p><strong>Use in Children</strong><br />The use in children is not recommended.</p><p><strong>If you use more Fibrosta &nbsp;than you should</strong><br />Your dose of Fibrosta is carefully monitored and checked by your doctor and pharmacist.</p><p>The most frequently reported symptom of overdose is bleeding. If you notice bleeding, you should notify your health care professional immediately.</p><p><strong>If you forget to use Fibrosta</strong><br />Your doctor will decide when to administer the dose.</p><p><strong>If you stop using Fibrosta</strong><br />Your doctor will decide when treatment should be stopped. However, if you wish to stop your treatment earlier, you should discuss other options with your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most common side effect of treatment with tirofiban<strong> </strong>is bleeding which could occur anywhere in the body. This can become serious and may, rarely, be fatal.</p><p>If side effects occur, they may need medical attention. While using tirofiban, if you develop any of the following symptoms, you should contact your doctor immediately:</p><ul><li>Signs of bleeding in the skull such as pain in the head, sensory impairments (visual or hearing), difficulties in speech, numbness or problems with movement or balance</li><li>Signs of internal bleeding such as coughing up blood or blood in your urine or stool</li><li>Signs of serious allergic reactions such as difficulties in breathing and dizziness</li></ul><p>Below is a list of side effects that have occurred in some people following treatment with tirofiban. The side effects are listed in decreasing order of frequency.</p><p><strong>Very common (may affect more than 1 in 10 people): </strong></p><ul><li>Bleeding after surgery</li><li>Bleeding under the skin at the site of an injection, or into a muscle, causing swelling</li><li>Small red bruises on the skin</li><li>Invisible blood in urine or stool</li><li>Feeling sick</li><li>Headache</li></ul><p><strong>Common (may affect up to 1 in 10 people): </strong></p><ul><li>Blood in urine</li><li>Coughing up of blood</li><li>Nose bleeds</li><li>Bleeding in the gums and mouth</li><li>Bleeding from vessel puncture site</li><li>Reduction in red blood cells (reduced haematocrit and haemoglobin)</li><li>Decreases in platelet count below 90,000/mm<sup>3</sup></li><li>Fever</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people): </strong></p><ul><li>Bleeding in the stomach or intestines</li><li>Vomiting of blood</li><li>Decreases in platelet count below 50,000/mm<sup>3</sup></li></ul><p><strong>Not known (frequency cannot be estimated from the available data): </strong></p><ul><li>Bleeding in the skull</li><li>Haematoma in the spinal region</li><li>Bleeding in the abdomen of the internal organs</li><li>Accumulation of blood around the heart</li><li>Bleeding in the lung</li><li>Acute and/or severe decreases in platelet counts below &lt; 20,000/mm<sup>3</sup></li><li>Severe allergic reactions with tightness of chest, hives or nettle rash, including reactions that cause difficulty in breathing and dizziness</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C. Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>After dilution the product should be used immediately. If not used immediately, in use storage conditions are the responsibility of the user and would normally not be longer than 24 hours at 2-8&deg;C.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. &nbsp;The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice visible particles or discolouration of the solution before use.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tirofiban hydrochloride monohydrate. &nbsp;</p><p>Each ml of Fibrosta 250 &micro;g/ml Concentrate for Solution for Infusion contains 281 &micro;g tirofiban hydrochloride monohydrate equivalent to 250 &micro;g tirofiban.</p><p>The other ingredients are sodium chloride, sodium citrate, citric acid, sodium hydroxide/hydrochloric acid and water for injection. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fibrosta 250 µg/ml Concentrate for Solution for Infusion is a clear colourless solution, essentially free from foreign contaminants or visible particles in 50 ml type I clear glass vials with grey bromo-butyl rubber stoppers and orange aluminium flip-off caps. 

Pack size: 1 Vial (50 ml).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong><br />Hikma Farmaceutica (Portugal), S.A.<br />Estrada do Rio Da M&oacute;,<br />n.&deg;8, 8A e 8B, Ferven&ccedil;a<br />2705-906 Terrugem<br />Sintra, Portugal<br />Tel: + (351-2) 19608410<br />Fax: + (351-2) 19615102</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2023; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستخدم فايبروستا للمساعدة في تدفق الدم إلى قلبك وللمساعدة في منع ألم الصدر والنوبات القلبية. ويعمل هذا الدواء من خلال منع الصفائح الدموية، الخلايا الموجودة في الدم، من تكوين جلطات دموية.&nbsp;</p><p dir="RTL">يمكن استخدام هذا الدواء أيضاً لدى المرضى الذين يتم توسيع أوعيتهم القلبية بواسطة بالون (التدخل التاجي عن طريق الجلد). وهي عملية، ربما يصاحبها إدخال أنبوب صغير (دعامة)، لتحسين تدفق الدم إلى القلب.&nbsp;</p><p dir="RTL">يوصف فايبروستا للاستخدام مع الأسبرين والهيبارين غير المجزأ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم فايبروستا</strong></p><ul dir="rtl"><li>إذا كنت تعاني من تحسس (فرط الحساسية) لتايروفيبان أو لأي من المواد الأخرى المستخدمة في تركيبة فايبروستا (المذكورة في القسم 6 &quot;ما هي محتويات فايبروستا&quot;).</li><li>إذا كنت تعاني من نزف داخلي أو سبق وأن تعرضت لنزف داخلي في غضون الثلاثين يوماً الماضية.</li><li>إذا تعرضت من قبل لنزف أو ورم في الدماغ أو اضطراب الأوعية الدموية في الدماغ.</li><li>إذا كنت تعاني من ارتفاع ضغط الدم يصعب السيطرة عليه (فرط ضغط الدم الخبيث).</li><li>إذا كنت تعاني من انخفاض في عدد الصفائح الدموية (قلة الصفيحات) أو مشكلات في تخثر الدم.</li><li>إذا كنت تعاني من قلّة الصفيحات أو إذا تلقيت علاجاً بفايبروستا أو دواء آخر من نفس مجموعة الأدوية سابقاً.</li><li>إذا عانيت سابقاً من سكتة دماغية في غضون آخر 30 يوماً أو تعرضت من قبل لأي سكتة دماغية مع نزف.</li><li>إذا تعرضت لإصابة خطيرة أو خضعت لعملية جراحية كبيرة خلال الأسابيع الستة الماضية.</li><li>إذا كنت تعاني من مرض شديد في الكبد.</li></ul><p dir="RTL">سيراجع الطبيب المتابع لحالتك تاريخك الطبي لمعرفة إذا ما كنت في خطر متزايد من أي آثار جانبية مرتبطة بإعطائك هذا الدواء.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />تحدث مع طبيبك قبل استخدام فايبروستا، إذا كنت تعاني أو عانيت في السابق من:</p><ul dir="rtl"><li>أي مشكلات طبية</li><li>أي نوع من الحساسية</li><li>الإنعاش القلبي الرئوي، أو الخزعة، أو الخضوع لعملية تفتيت حصى الكلى في غضون الأسبوعين الماضيين</li><li>التعرض لإصابة خطيرة أو الخضوع لعملية جراحية كبيرة في غضون الأشهر الثلاثة الماضية</li><li>قرحة في المعدة أو الأمعاء (الاثني عشر) في غضون الأشهر الثلاثة الماضية</li><li>اضطراب نزفي مؤخراً (خلال عام واحد) مثل نزف في المعدة أو الأمعاء، أو دم في البول أو البراز</li><li>عملية حديثة بالعمود الفقري</li><li>إصابة مسبقة أو أعراض لانقسام الأبهر (تسلُّخ الأبهر)</li><li>ارتفاع ضغط الدم بشكل يصعب السيطرة عليه (فرط ضغط الدم)</li><li>التهاب البطانة حول القلب (التهاب غلاف القلب)</li><li>التهاب الأوعية الدموية (الالتهاب الوعائي)</li><li>مشكلات في الأوعية الدموية في مؤخرة العين (شبكية العين)</li><li>العلاج بالأدوية التي تساعد على منع جلطات الدم أو إذابتها</li><li>مشكلات في الكلى</li><li>إدخال خط وريدي خاص تحت عظمة الترقوة خلال 24 ساعة الماضية</li><li>فشل القلب</li><li>انخفاض شديد في ضغط الدم بسبب فشل القلب (صدمة قلبية)</li><li>اضطراب في الكبد</li><li>انخفاض عدد كريات الدم أو فقر الدم</li></ul><p dir="RTL"><strong>الأدوية الأخرى وفايبروستا</strong><br />بشكل عام، يمكن استخدام تايروفيبان مع أدوية أخرى. أخبر طبيبك إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أي أدوية أخرى، ومنها الأدوية التي تُصرف دون وصفة طبية، لأن بعض الأدوية قد تؤثر على عمل بعضها البعض. ومن المهم بشكل خاص أن تخبر طبيبك إذا كنت تتناول أدوية أخرى تساعد على منع الدم من التجلط مثل الوارفارين.</p><p><strong>الفايبروستا مع الطعام والشراب</strong><br />لا يؤثر الطعام والشراب على هذا الدواء.</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />اطلبي النصيحة من طبيبك قبل استخدام هذا الدواء إذا كنتِ حاملاً أو مرضعاً، تعتقدين بأنكِ حاملاً أو تخططين لذلك.</p><p><strong>القيادة واستخدام الآلات</strong><br />لن تكون قادراً على القيادة أو استخدام الآلات في أثناء استخدام فايبروستا نظراً لحالتك المرضية.</p><p><strong>&nbsp;يحتوي فايبروستا على الصوديوم</strong><br />يحتوي فايبروستا على الصوديوم. يحتوي هذا الدواء على 189 ملغم صوديوم (المكون الرئيسي للطبخ/ملح الطعام) في كل 50 مللتر. وهذا يكافئ 9.45% من الحد الأقصى الموصى به من الحصة الغذائية اليومية من الصوديوم للشخص البالغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يصف فايبروستا طبيب مؤهل من ذوي الخبرة في معالجة النوبات القلبية.</p><p dir="RTL">لقد تم إعطاؤك، أو على وشك أن يتم إعطاؤك، فايبروستا في الوريد. سيقرر طبيبك الجرعة المناسبة، بناءً على حالتك ووزنك.</p><p dir="RTL"><strong>الاستخدام لدى الأطفال</strong><br />لا&nbsp;ينصح باستخدام هذا الدواء لدى الأطفال.</p><p><strong>إذا تناولت فايبروستا أكثر من اللازم</strong><br />يتم مراقبة جرعتك من فايبروستا بعناية والتحقق منها من قبل الطبيب والصيدلي.</p><p>يعد النزف أكثر أعراض الجرعة الزائدة المُبلّغ عنها بشكل متكرر. إذا لاحظت حدوث نزف، يجب عليك إخبار اختصاصي الرعاية الصحية المتابع لحالتك على الفور.</p><p><strong>إذا نسيت استخدام فايبروستا</strong><br />سيقرر طبيبك موعد استخدام الجرعة.</p><p><strong>&nbsp;إذا توقفت عن استخدام فايبروستا</strong><br />سيقرر طبيبك متى يجب إيقاف العلاج. ومع ذلك، إذا كنت ترغب في إيقاف علاجك في وقت مبكر، فيجب عليك مناقشة الخيارات الأخرى مع طبيبك.</p><p>إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">التأثير الجانبي الأكثر شيوعاً للعلاج باستخدام تايروفيبان هو النزف الذي يمكن أن يحدث في أي مكان في الجسم. يمكن أن يصبح هذا النزف خطيراً ونادراً ما يكون مميتاً.</p><p dir="RTL">قد يلزم عناية طبية في حال حدوث آثار جانبية. أثناء استخدام تايروفيبان، إذا ظهرت عليك أي من الأعراض التالية، يجب عليك الاتصال بطبيبك على الفور:</p><ul dir="rtl"><li>علامات النزف في الجمجمة مثل ألم في الرأس، أو اضطراب حسي (بصري أو سمعي)، أو صعوبات في الكلام، أو تنميل أو مشكلات في الحركة أو التوازن</li><li>علامات النزف الداخلي مثل سعال دموي أو وجود دم في البول أو البراز</li><li>علامات لردود فعل تحسسية خطيرة مثل صعوبة التنفس والدوخة</li></ul><p dir="RTL">فيما يلي قائمة بالآثار الجانبية التي حدثت لدى بعض الأشخاص بعد العلاج بتايروفيبان. يتم ذكر الآثار الجانبية بترتيب تنازلي لتكرارها.</p><p dir="RTL"><strong>شائعة جداً (قد تؤثر في أكثر من شخص من بين كل 10 أشخاص): </strong></p><ul dir="rtl"><li>النزف بعد الجراحة</li><li>نزف تحت الجلد في موضع الحقن، أو في العضل، ما يسبب تورم</li><li>كدمات حمراء صغيرة على الجلد</li><li>دم غير مرئي في البول أو البراز</li><li>الشعور بالإعياء</li><li>صداع</li></ul><p dir="RTL"><strong>شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 10 أشخاص): </strong></p><ul dir="rtl"><li>دم في البول</li><li>سعال دموي</li><li>نزيف من الأنف</li><li>نزف في اللثة والفم</li><li>نزف من موضع ثقب الوعاء الدموي</li><li>انخفاض في خلايا الدم الحمراء (انخفاض الهيماتوكريت والهيموجلوبين)</li><li>انخفاض في عدد الصفائح الدموية أقل من 90000/مم<sup>3</sup></li><li>الحمّى</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 100 شخص): </strong></p><ul dir="rtl"><li>نزف في المعدة أو الأمعاء</li><li>قيء دموي</li><li>انخفاض في عدد الصفائح الدموية أقل من 50000/ مم<sup>3</sup></li></ul><p dir="RTL"><strong>غير معروف</strong><strong>ة</strong><strong> (لا يمكن تقدير التكرار من البيانات المتاحة): </strong></p><ul dir="rtl"><li>نزف في الجمجمة</li><li>ورم دموي في منطقة العمود الفقري</li><li>نزف في البطن من الأعضاء الداخلية</li><li>تراكم الدم حول القلب</li><li>نزف في الرئة</li><li>انخفاض حاد و/أو شديد في عدد الصفائح الدموية أقل من 20000/ مم<sup>3</sup></li><li>ردود فعل تحسسية شديدة مع ضيق في الصدر، شرى أو طفح جلدي، بما في ذلك ردود الفعل التي تسبب صعوبة في التنفس والدوخة</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية. لا يحفظ مجمداً.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">يجب استخدام المستحضر بعد التخفيف على الفور. إذا لم يتم استخدامه على الفور، تقع مسؤولية ظروف التخزين أثناء الاستخدام على المستخدم، ويجب ألا تزيد عادةً عن 24 ساعة عند درجة حرارة 2-8&deg; مئوية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;.&nbsp; يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت وجود جزيئات مرئية أو تغير لون المحلول قبل الاستخدام.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.&nbsp; اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي هيدروكلوريد التايروفيبان أحادي الماء.</p><p dir="RTL">يحتوي كل مللتر من فايبروستا 250 مكغم/مللتر مركز للتخفيف للتسريب على 281 مكغم هيدروكلوريد التايروفيبان أحادي الماء يكافئ 250 مكغم تايروفيبان.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي كلوريد الصوديوم، سيترات الصوديوم، حمض السيتريك، هيدروكسيد الصوديوم/حمض الهيدروكلوريك وماء معد للحقن.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فايبروستا 250 مكغم/مللتر مركز للتخفيف للتسريب هو محلول صافٍ عديم اللون، وخالٍ بشكل أساسي من الشوائب الغريبة أو الجسيمات المرئية في زجاجات شفافة من النوع رقم واحد بحجم 50 مللتر مع سدادات مطاطية رمادية من البروموبوتيل وأغطية برتقالية من الألومنيوم قابلة للفتح لأعلى.</p><p dir="RTL">حجم العبوة: زجاجة واحدة (50 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة</strong><br />شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة<br />إسترادا دو ريو دا مو،<br /><img alt="" width="160" height="18" src="data:image/png;base64,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" /><br />2705-906 تيروجيم<br />سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 11/2023؛ رقم النسخة SA1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fibrosta 250 µg/ml Concentrate for Solution for Infusion


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 281 µg tirofiban hydrochloride monohydrate equivalent to 250 µg tirofiban.

Excipient with known effect: Sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for Solution for Infusion.

Clear colourless solution, essentially free from foreign contaminants or visible particles.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fibrosta is indicated for the prevention of early myocardial infarction in adult patients presenting with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes.</p><p>Patients most likely to benefit from Fibrosta treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI). Fibrosta is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI (see sections 4.2 and 5.1).</p><p>Fibrosta is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This product is for hospital use only, by specialist physicians experienced in the management of acute coronary syndromes.</p><p>Fibrosta Concentrate must be diluted before use.</p><p>Fibrosta should be administered with unfractionated heparin and oral antiplatelet therapy, including ASA.</p><p><strong>Posology</strong><br />In patients who are managed with an early invasive strategy for NSTE-ACS but not planned to undergo angiography for at least 4 hours and up to 48 hours after diagnosis, Fibrosta is given intravenously at an initial infusion rate of 0.4 microgram/kg/min for 30 minutes. At the end of the initial infusion, Fibrosta should be continued at a maintenance infusion rate of 0.1 microgram/kg/min. Fibrosta should be given with unfractionated heparin (usually an intravenous bolus of 50-60 units [U]/kg simultaneously with the start of Fibrosta therapy, then approximately 1,000 U per hour, titrated on the basis of the activated thromboplastin time [APTT], which should be about twice the normal value) and oral antiplatelet therapy, including but not limited to ASA (see section 5.1), unless contra-indicated.</p><p>In NSTE-ACS patients planned to undergo PCI within the first 4 hours of diagnosis or in patients with acute myocardial infarction intended for primary PCI, Fibrosta should be administered utilizing an initial bolus of 25 microgram/kg given over a 3 minute period, followed by a continuous infusion at a rate of 0.15 microgram/kg/min for 12-24, and up to 48 hours. Fibrosta should be administered with unfractionated heparin (dosage as above) and oral antiplatelet therapy, including but not limited to ASA (see section 5.1), unless contra-indicated.</p><p><em>Elderly</em><br />No dosage adjustment is necessary for the elderly (see section 4.4).</p><p><em>Patients with severe kidney failure</em><br />In severe kidney failure (creatinine clearance &lt;30 ml/min) the dosage of Fibrosta should be reduced by 50% (see sections 4.4 and 5.2).</p><p><em>Paediatric population</em><br />The safety and efficacy of tirofiban in children aged &lt; 18 years have not been established.</p><p>No data are available.</p><p>Table 1 is provided as a guide to dosage adjustment by weight.</p><p><strong>Fibrosta </strong><strong>Concentrate must be first diluted as noted under&nbsp;<em>Instructions for Use</em>.</strong></p><p><strong>Table 1: Dosing Table</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:109%"><tbody><tr><td rowspan="2"><p><strong>Patient Weight (kg)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>0.4 microgram/kg/min Loading Dose Regimen</strong></p><p><strong>Most Patients</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>0.4 microgram/kg/min Loading Dose Regimen</strong></p><p><strong>Severe Kidney Failure</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>25 microgram/kg</strong></p><p><strong>Dose Bolus Regimen</strong></p><p><strong>Most Patients</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>25 microgram/kg</strong></p><p><strong>Dose Bolus Regimen</strong></p><p><strong>Severe Kidney Failure</strong></p></td></tr><tr><td style="vertical-align:top"><p>30 min Loading Infusion Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>Maintenance Infusion Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>30 min Loading Infusion Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>Maintenance Infusion Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>Bolus</p><p>(ml)</p></td><td style="vertical-align:top"><p>Maintenance Infusion Rate</p><p>(ml/hr)</p></td><td style="vertical-align:top"><p>Bolus</p><p>(ml)</p></td><td style="vertical-align:top"><p>Maintenance Infusion Rate</p><p>(ml/hr)</p></td></tr><tr><td style="vertical-align:top"><p>30-37</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>38-45</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>46-54</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>55-62</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>63-70</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>71-79</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>80-87</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>88-95</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>96-104</p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>105-112</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>113-120</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>58</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>121-128</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>62</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>129-137</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>138-145</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>146-153</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>13</p></td></tr></tbody></table><p><em>Start and duration of therapy with Fibrosta</em><br />In patients who are managed with an early invasive strategy for NSTE-ACS but not planned to undergo angiography for at least 4 hours and up to 48 hours after diagnosis, Fibrosta 0.4 microgram/kg/min loading dose regimen should be initiated upon diagnosis. The recommended duration of the maintenance infusion should be at least 48 hours. Infusion of Fibrosta and unfractionated heparin may be continued during coronary angiography and should be maintained for at least 12 hours and not more than 24 hours after angioplasty/atherectomy. Once a patient is clinically stable and no coronary intervention procedure is planned by the treating physician, the infusion should be discontinued. The entire duration of treatment should not exceed 108 hours.</p><p>If the patient diagnosed with NSTE-ACS and managed with an invasive strategy undergoes angiography within 4 hours after the diagnosis, the Fibrosta 25 microgram/kg dose bolus regimen should be initiated at the start of PCI with the infusion continued for 12-24 hours and up to 48 hours.</p><p>In patients with acute myocardial infarction intended for primary PCI, the 25 microgram/kg dose bolus regimen should be initiated as soon as possible after diagnosis.</p><p><em>Concurrent therapy (unfractionated heparin, oral antiplatelet therapy, including ASA)</em><br />Treatment with unfractionated heparin is initiated with an i.v. bolus of 50-60 U/kg and then continued with a maintenance infusion of 1,000 U per hour. The heparin dosage is titrated to maintain an APTT of approximately twice the normal value.</p><p>Unless contra-indicated, all patients should receive oral antiplatelet agents, including but not limited to ASA, before the start of Fibrosta (see section 5.1). This medication should be continued at least for the duration of the infusion of Fibrosta.</p><p>Most studies investigating the administration of tirofiban as an adjunct to PCI have used ASA in combination with clopidogrel as oral antiplatelet therapy. The efficacy of the combination of tirofiban with either prasugrel or ticagrelor has not been established in randomised controlled trials.</p><p>If angioplasty (PCI) is required, heparin should be stopped after PCI, and the sheaths should be withdrawn once coagulation has returned to normal, e.g. when the activated clotting time (ACT) is less than 180 seconds (usually 2-6 hours after discontinuation of heparin).</p><p><strong>Method of administration</strong><br /><em>Instructions for use</em><br />Fibrosta concentrate must be diluted before use:</p><ol><li>Draw 50 ml from a 250 ml container of sterile 0.9% saline or 5% glucose in water and replace with 50 ml Fibrosta (from one 50 ml puncture vial) to make up a concentration of 50 microgram/ml. Mix well before use.</li><li>Use according to the dosage table above.</li></ol><p>Where the solution and container permit, parenteral drugs should be inspected for visible particles or discoloration before use.</p><p>Fibrosta should only be given intravenously and may be administered with unfractionated heparin through the same infusion tube.</p><p>It is recommended that Fibrosta be administered with a calibrated infusion set using sterile equipment.</p><p>Care should be taken to ensure that no prolongation of the infusion of the initial dose occurs and that miscalculation of the infusion rates for the maintenance dose on the basis of the patient&#39;s weight is avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fibrosta is contra-indicated in patients who are hypersensitive to the active substance or to any of the excipients of the preparation listed in section 6.1 or who developed thrombocytopenia during earlier use of a GP IIb/IIIa receptor antagonist.

Since inhibition of platelet aggregation increases the bleeding risk, Fibrosta is contra-indicated in patients with:
• History of stroke within 30 days or any history of haemorrhagic stroke.
• Known history of intracranial disease (e.g. neoplasm, arteriovenous malformation, aneurysm).
• Active or recent (within the previous 30 days of treatment) clinically relevant bleeding (e.g. gastro-intestinal bleeding).
• Malignant hypertension.
• Relevant trauma or major surgical intervention within the past six weeks.
• Thrombocytopenia (platelet count <100,000/mm3), disorders of platelet function.
• Clotting disturbances (e.g. prothrombin time >1.3 times normal or INR [International Normalised Ratio] >1.5).
• Severe liver failure.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The administration of Fibrosta alone without unfractionated heparin is not recommended.</p><p>There is limited experience with concomitant administration of tirofiban with enoxaparin (see sections 5.1 and 5.2). The concomitant administration of tirofiban with enoxaparin is associated with a higher frequency of cutaneous and oral bleeding events, but not in TIMI bleeds**, when compared with the concomitant administration of tirofiban and unfractionated heparin. An increased risk of serious bleeding events associated with the concomitant administration of tirofiban and enoxaparin cannot be excluded, particularly in patients given additional unfractionated heparin in conjunction with angiography and/or PCI. The efficacy of tirofiban in combination with enoxaparin has not been established. The safety and efficacy of tirofiban with other low molecular weight heparins has not been investigated.</p><p>There is insufficient experience with the use of tirofiban hydrochloride in the following diseases and conditions, however, an increased risk of bleeding is suspected. Therefore, tirofiban hydrochloride is not recommended in:</p><ul><li>Traumatic or protracted cardiopulmonary resuscitation, organ biopsy or lithotripsy within the past two weeks</li><li>Severe trauma or major surgery &gt;6 weeks but &lt;3 months previously</li><li>Active peptic ulcer within the past three months</li><li>Uncontrolled hypertension (&gt;180/110 mm Hg)</li><li>Acute pericarditis</li><li>Active or a known history of vasculitis</li><li>Suspected aortic dissection</li><li>Haemorrhagic retinopathy</li><li>Occult blood in the stool or haematuria</li><li>Thrombolytic therapy (see section 4.5).</li><li>Concurrent use of drugs that increase the risk of bleeding to a relevant degree (see section 4.5).</li></ul><p>There is no therapeutic experience with tirofiban hydrochloride in patients for whom thrombolytic therapy is indicated. Consequently, the use of tirofiban hydrochloride is not recommended in combination with thrombolytic therapy.</p><p>Fibrosta infusion should be stopped immediately if circumstances arise that necessitate thrombolytic therapy (including acute occlusion during PCI) or if the patient must undergo an emergency coronary artery bypass graft (CABG) operation or requires an intra-aortic balloon pump.</p><p><em>Paediatric population</em><br />There is no therapeutic experience with tirofiban in children, thus, the use of tirofiban is not recommended in these patients.</p><p><em>Other precautionary notes and measures</em><br />There are insufficient data regarding the re-administration of tirofiban.</p><p>Patients should be carefully monitored for bleeding during treatment with Fibrosta. If treatment of haemorrhage is necessary, discontinuation of Fibrosta should be considered (see section 4.9). In cases of major or uncontrollable bleeding, tirofiban hydrochloride should be discontinued immediately.</p><p>Fibrosta should be used with special caution in the following conditions and patient groups:</p><ul><li>Recent clinically relevant bleeding (less than one year)</li><li>Puncture of a non-compressible vessel within 24 hours before administration of Fibrosta</li><li>Recent epidural procedure (including lumbar puncture and spinal anaesthesia)</li><li>Severe acute or chronic heart failure</li><li>Cardiogenic shock</li><li>Mild to moderate liver insufficiency</li><li>Platelet count &lt;150,000/mm3, known history of coagulopathy or platelet function disturbance or thrombocytopenia</li><li>Haemoglobin concentration less than 11 g/dl or haematocrit &lt;34%.</li></ul><p>Special caution should be used during concurrent administration of ticlopidine, clopidogrel, adenosine, dipyridamole, sulfinpyrazone, and prostacyclin.</p><p><em>Efficacy with regard to dose</em><br />The administration of a 10 microgram/kg bolus regimen of tirofiban failed to show noninferiority in clinically relevant endpoints at 30 days compared to abciximab (see section 5.1).</p><p><em>Elderly patients, female patients, and patients with low body weight</em><br />Elderly and/or female patients had a higher incidence of bleeding complications than younger or male patients, respectively. Patients with a low body weight had a higher incidence of bleeding than patients with a higher body weight. For these reasons Fibrosta should be used with caution in these patients and the heparin effect should be carefully monitored.</p><p><em>Impaired renal function</em><br />There is evidence from clinical studies that the risk of bleeding increases with decreasing creatinine clearance and hence also reduced plasma clearance of tirofiban. Patients with decreased renal function (creatinine clearance &lt;60ml/min) should therefore be carefully monitored for bleeding during treatment with Fibrosta and the heparin effect should be carefully monitored. In severe kidney failure the Fibrosta dosage should be reduced (see section 4.2).</p><p><em>Femoral artery line</em><br />During treatment with Fibrosta there is a significant increase in bleeding rates, especially in the femoral artery area, where the catheter sheath is introduced. Care should be taken to ensure that only the anterior wall of the femoral artery is punctured. Arterial sheaths may be removed when coagulation has returned to normal, e.g. when activated clotting time (ACT) is less than 180 seconds, (usually 2&ndash;6 hours after discontinuation of heparin).</p><p>After removal of the introducer sheath, careful haemostasis should be ensured under close observation.</p><p><em>General nursing care</em><br />The number of vascular punctures, and intramuscular injections should be minimised during the treatment with Fibrosta. I.V. access should only be obtained at compressible sites of the body. All vascular puncture sites should be documented and closely monitored. The use of urinary catheters, nasotracheal intubation and nasogastric tubes should be critically considered.</p><p><em>Monitoring of laboratory values</em><br />Platelet count, haemoglobin and haematocrit levels should be determined before treatment with Fibrosta as well as within 2-6 hours after start of therapy with Fibrosta and at least once daily thereafter while on therapy (or more often if there is evidence of a marked decrease). In patients who have previously received GPIIb/IIIa receptor antagonists (cross reactivity can occur), the platelet count should be monitored immediately e.g. within the first hour of administration after re-exposure (see section 4.8). If the platelet count falls below 90,000/mm<sup>3</sup>, further platelet counts should be carried out in order to rule out pseudothrombocytopenia. If thrombocytopenia is confirmed, Fibrosta and heparin should be discontinued. Patients should be monitored for bleeding and treated if necessary (see section 4.9).</p><p>In addition, activated thromboplastin time (APTT) should be determined before treatment and the anticoagulant effects of heparin should be carefully monitored by repeated determinations of APTT and the dose should be adjusted accordingly (see section 4.2). Potentially life-threatening bleeding may occur especially when heparin is administered with other products affecting haemostasis, such as GPIIb/IIIa receptor antagonists.</p><p><strong>Fibrosta contains sodium</strong><br />Fibrosta contains sodium. This medicine contains 189 mg sodium per 50 ml, equivalent to 9.45% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>**TIMI major bleeds are defined as a haemoglobin drop of &gt; 50 g/l with or without an identified site, intracranial haemorrhage, or cardiac tamponade. TIMI minor bleeds are defined as a haemoglobin drop of &gt; 30 g/l but &le; 50 g/l with bleeding from a known site or spontaneous gross haematuria, haematemesis, or haemoptysis. TIMI &quot;loss no site&quot; is defined as a haemoglobin drop &gt; 40 g/l but &lt; 50 g/l without an identified bleeding site.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of several platelet aggregation inhibitors increases the risk of bleeding, likewise their combination with heparin, warfarin and thrombolytics. Clinical and biological parameters of haemostasis should be regularly monitored.</p><p>The concomitant administration of Fibrosta and ASA increases the inhibition of platelet aggregation to a greater extent than ASA alone, as measured by&nbsp;<em>ex vivo</em>&nbsp;APD-induced platelet aggregation test. The concomitant administration of Fibrosta and unfractionated heparin increases the prolongation of the bleeding time to a greater extent as compared to unfractionated heparin alone.</p><p>With the concurrent use of Fibrosta, unfractionated heparin, ASA, and clopidogrel there was a comparable incidence of bleeding than when only unfractionated heparin, ASA, and clopidogrel were used together (see sections 4.4 and 4.8).</p><p>Fibrosta prolonged bleeding time; however, the combined administration of Fibrosta and ticlopidine did not additionally affect bleeding time.</p><p>Concomitant use of warfarin with Fibrosta plus heparin was associated with an increased risk of bleeding.</p><p>Fibrosta is not recommended in thrombolytic therapy - concurrent or less than 48 hours before administration of tirofiban hydrochloride or concurrent use of drugs that increase the risk of bleeding to a relevant degree (e.g. oral anticoagulants, other parenteral GP IIb/IIIa inhibitors, dextran solutions). There is insufficient experience with the use of tirofiban hydrochloride in these conditions; however, an increased risk of bleeding is suspected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />There are no or limited amount of data from the use of tirofiban hydrochloride in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). tirofiban is not recommended during pregnancy unless clearly necessary<strong><em>.</em></strong></p><p><em>&nbsp;</em><strong>Breastfeeding</strong><br />It is unknown whether tirofiban hydrochloride is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of tirofiban hydrochloride in milk (for details see section 5.3). A risk to the newborn cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue tirofiban therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</p><p><em>&nbsp;</em><strong>Fertility</strong><br />Fertility and reproductive performance were not affected in studies with male and female rats treated with different doses of tirofiban hydrochloride (see section 5.3).</p><p>However, animal studies are insufficient to draw conclusions with respect to reproductive toxicity in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;a. Summary of safety profile</strong><br />The most common adverse reaction reported during therapy with tirofiban, when used concomitantly with heparin, aspirin and other oral anti-platelet agents, was bleeding, which usually involved mild mucocutaneous bleeding or mild catheterization-site bleeding.</p><p>Gastro-intestinal, retro-peritoneal, intracranial, haemorrhoidal and post-operative bleeding, epidural haematoma in the spinal region, haemopericardium and pulmonary (alveolar) haemorrhage have also been reported. Rates of TIMI major and intracranial bleeding in the pivotal tirofiban studies were &le;2.2% and &lt;0.1%, respectively. The most serious adverse reaction was fatal bleeding.</p><p>In the pivotal studies, administration of tirofiban was associated with thrombocytopenia (platelet count &lt;90,000/mm<sup>3</sup>), occurring in 1.5% of patients treated with tirofiban and heparin. The incidence of severe thrombocytopenia (platelet count &lt;50,000/mm<sup>3</sup>) was 0.3%. The most common non-bleeding adverse drug reactions associated with tirofiban given concurrently with heparin were nausea (1.7%), fever (1.5%) and headache (1.1%).</p><p><strong>b. Tabulated summary of adverse reactions</strong><br />Table 2 lists the adverse reactions based on experience from six double-blind controlled clinical studies (including 1953 patients receiving tirofiban plus heparin) as well as adverse reactions reported from post-marketing experience. Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (&ge; 1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Because post-marketing events are derived from spontaneous reports from a population of uncertain size, it is not possible to determine their exact incidence. Therefore, the frequency of these adverse reactions is categorised as not known.</p><p><strong>Table 2: Undesirable effects in clinical studies and from post-marketing experience.</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Very common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Acute and/or severe (&lt;20,000/mm3) decreases in platelet counts</p></td></tr><tr><td style="vertical-align:top"><p>Immune System Disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Severe allergic reactions including anaphylactic reactions.</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Intracranial bleeding, spinal epidural haematoma</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hemopericardium</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Haematoma</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haemoptysis, epistaxis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pulmonary (alveolar) haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Oral haemorrhage gingival haemorrhage</p></td><td style="vertical-align:top"><p>GI haemorrhage, haematemesis</p></td><td style="vertical-align:top"><p>Retroperitoneal bleeding</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Ecchymosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Post-operative haemorrhage*</p></td><td style="vertical-align:top"><p>Vessel puncture site haemorrhage</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Occult blood in stool or urine</p></td><td style="vertical-align:top"><p>Decreases in haematocrit and haemoglobin, platelet counts &lt;90,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>Platelet counts &lt;50,000/mm<sup>3</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><strong>*Primarily related to catheterization sites.</strong></p><p><strong>c. Description of selected adverse reactions</strong><br /><em>Bleeding</em><br />Both, with the tirofiban 0.4 microgram/kg/min infusion regimen and the 25 microgram/kg dose bolus regimen, rates of major bleeding complications are low and not significantly increased.</p><p>In the PRISM-PLUS study, using the tirofiban 0.4 microgram/kg/min infusion regimen, the incidence of TIMI major bleeding was 1.4% for tirofiban in combination with heparin and 0.8% for heparin alone. The incidence of TIMI minor bleeding was 10.5% for tirofiban in combination with heparin and 8.0% for heparin alone. The percentage of patients who received a transfusion was 4.0% for tirofiban in combination with heparin and 2.8% for heparin alone.</p><p>With the tirofiban 25 microgram/kg dose bolus regimen, data from the ADVANCE study suggest that the number of bleeding events is low and does not seem to be significantly increased compared to placebo. There were no TIMI major bleedings and no transfusions in either group. TIMI minor bleeding with the tirofiban 25 microgram/kg dose bolus regimen was 4% as compared with 1% in the placebo arm p=0.19).</p><p>In the On-TIME 2 study, there were no significant differences in the incidence of TIMI major bleeding (3.4% vs. 2.9% p =0.58) and TIMI minor bleeding (5.9% vs. 4.4%; p=0.206) between the tirofiban 25 microgram/kg dose bolus regimen and the control arm.</p><p>The rates of TIMI major (2.4% vs. 1.6%; p=0.44) or minor bleeding (4.8% vs. 6.2%; p=0.4) were also not significantly different between the tirofiban 25 microgram/kg dose and the standard dose of abciximab, which were compared in the MULTISTRATEGY study.</p><p>Based upon an assessment of haemorrhagic complications performed in the context of a meta-analysis (n=4076 ACS patients), the tirofiban 25 microgram/kg dose bolus regimen does not significantly increase the rates of major bleeding, or thrombocytopenia, when compared to placebo. When considering the trials of the tirofiban 25 microgram/kg bolus regimen compared with abciximab, individual study results do not demonstrate a significant difference in major bleeding between the two treatments<em>.</em></p><p><em>Thrombocytopenia</em><br />During tirofiban therapy, acute decreases in platelet count or thrombocytopenia occurred more frequently than in the placebo group. These decreases were reversible upon discontinuation of tirofiban. Acute and severe platelet (platelet counts &lt;20,000/mm<sup>3</sup>) decreases have been observed in patients with no prior history of thrombocytopenia upon re-administration of GPIIb/IIIa receptor antagonists and may be associated with chills, low-grade fever or bleeding complications.</p><p>Analysis of the studies comparing the 25 microgram/kg dose bolus regimen against abciximab yielded a significantly lower rate of thrombocytopenia for tirofiban (0.45% vs. 1.7%; OR=0.31; p=0.004).</p><p><em>Allergic reactions</em><br />Severe allergic reactions (e.g., bronchospasm, urticaria) including anaphylactic reactions have occurred during initial treatment (also on the first day) and during readministration of tirofiban. Some cases have been associated with severe thrombocytopenia (platelet counts &lt;10,000/mm<sup>3</sup>).</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inadvertent overdose with tirofiban hydrochloride occurred in the clinical studies, up to 50 microgram/kg as a three minute bolus or 1.2 microgram/kg/min as an initial infusion. Overdose with up to 1.47 microgram/kg/min as a maintenance infusion rate has also occurred.</p><p><strong>a) Symptoms of overdose</strong><br />The symptom of overdose most commonly reported was bleeding, usually mucosal bleeding and localised bleeding at the arterial puncture site for cardiac catheterisation but also single cases of intracranial haemorrhages and retroperitoneal bleedings (see sections 4.4 and 5.1).</p><p><strong>b) Measures</strong><br />Overdose with tirofiban hydrochloride should be treated in accordance with the patient&#39;s condition and the attending physician&#39;s assessment. If treatment of haemorrhage is necessary, the Fibrosta infusion should be discontinued. Transfusions of blood and/or thrombocytes should also be considered. Fibrosta can be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Blood and blood forming organs &ndash; antithrombotic agents &ndash;antithrombotic agents &ndash; Platelet aggregation inhibitors excl. heparin</p><p>ATC-Code: B01A C17</p><p><strong>Mechanism of action</strong><br />Tirofiban hydrochloride (tirofiban) is a non-peptidal antagonist of the GP IIb/IIIa receptor, an important platelet surface receptor involved in platelet aggregation. Tirofiban prevents fibrinogen from binding to the GP IIb/IIIa receptor, thus blocking platelet aggregation.</p><p>Tirofiban leads to inhibition of platelet function, evidenced by its ability to inhibit ex vivo ADP-induced platelet aggregation and to prolong bleeding time (BT). Platelet function returns to baseline within eight hours after discontinuation.</p><p>The extent of this inhibition runs parallel to the tirofiban plasma concentration.</p><p><strong>Pharmacodynamic effects</strong><br />In the 0.4 microgram/kg/min infusion regimen of tirofiban, in the presence of unfractionated heparin and ASA, tirofiban produced a more than 70% (median 89%) inhibition of ex vivo ADP-induced platelet aggregation in 93% of the patients, and a prolongation of the bleeding time by a factor of 2.9 during infusion. Inhibition was achieved rapidly with the 30-minute loading infusion and was maintained over the duration of the infusion.</p><p>The tirofiban 25 microgram/kg dose bolus regimen (followed by 18-24 hour maintenance infusion of 0.15 microgram/kg/min), in the presence of unfractionated heparin and oral antiplatelet therapy, produced an average ADP-induced inhibition of maximal aggregation 15 to 60 minutes after onset of treatment of 92% to 95% as measured with light transmission aggregometry (LTA).</p><p><strong>Clinical efficacy and safety</strong><br /><em>PRISM-PLUS study</em><br />The double-blind, multicentre, controlled PRISM-PLUS study compared the efficacy of tirofiban and unfractionated heparin (n=773) versus unfractionated heparin (n=797) in patients with unstable angina (UA) or acute non-Q-wave myocardial infarction (NQWMI) with prolonged repetitive anginal pain or post-infarction angina, accompanied by new transient or persistent ST-T wave changes or elevated cardiac enzymes.</p><p>Patients were randomised to either tirofiban (30 minute loading infusion of 0.4 microgram/kg/min followed by a maintenance infusion of 0.10 microgram/kg/min) and heparin (bolus of 5,000 units (U) followed by an infusion of 1,000 U/hr titrated to maintain an activated partial thromboplastin time (APTT) of approximately two times control), or heparin alone.</p><p>All patients received ASA unless contraindicated. Study drug was initiated within 12 hours after the last anginal episode. Patients were treated for 48 hours, after which they underwent angiography and possibly angioplasty/atherectomy, if indicated, while tirofiban was continued. tirofiban was infused for a mean period of 71.3 hours.</p><p>The combined primary study end-point was the occurrence of refractory ischaemia, myocardial infarction or death at seven days after the start of tirofiban.</p><p>At 7 days, the primary end-point, there was a 32% risk reduction (RR) (12.9% vs. 17.9%) in the tirofiban group for the combined end-point (p=0.004): this represents approximately 50 events avoided for 1,000 patients treated. After 30 days the RR for the composite end-point of death, MI, refractory ischaemic conditions, or readmissions for UA was 22% (18.5% vs. 22.3%; p=0.029). After six months the relative risk of composite of death, MI, refractory ischaemic conditions, or readmissions for UA was reduced by 19% (27.7% vs. 32.1% ; p=0.024).</p><p>Regarding the composite of death or MI, at seven days for the tirofiban group there was a 43% RR (4.9% vs. 8.3%; p=0.006); at 30 days the RR was 30% (8.7% vs. 11.9%; p=0.027) and at 6 months the RR was 23% (12.3% vs. 15.3%; p=0.063).</p><p>The reduction of MI in patients receiving tirofiban appeared early during treatment (within the first 48 hours) and was maintained through 6 months. In the 30% of patients who underwent angioplasty/atherectomy during initial hospitalisation, there was a 46% RR (8.8% vs. 15.2%) for the primary composite endpoint at 30 days as well as a 43% RR (5.9% vs. 10.2%) for death or MI.</p><p>Based on a safety study, the concomitant administration of tirofiban (30 minute loading dose of [0.4 microgram/kg/min] followed by a maintenance infusion of 0.1 microgram/kg/min for up to 108 hours) with enoxaparin (n=315) was compared to the concomitant administration of tirofiban with unfractionated heparin (n=210) in patients presenting with UA and NQWMI. Patients in the enoxaparin group received a 1.0 milligram/kg subcutaneous injection every 12 hours for a period of at least 24 hours and a maximum duration of 96 hours. Patients randomised to unfractionated heparin received a 5000-unit intravenous bolus followed by a maintenance infusion of 1000 units per hour for at least 24 hours and a maximum duration of 108 hours. The total TIMI bleed rate was 3.5% for the tirofiban /enoxaparin group and 4.8% for the tirofiban /unfractionated heparin group. Although there was a significant difference in the rates of cutaneous bleeds between the two groups (29.2% in the enoxaparin converted to unfractionated heparin group and 15.2% in the unfractionated heparin group), there were no TIMI major bleeds (see section 4.4) in either group. The efficacy of tirofiban in combination with enoxaparin has not been established.</p><p>PRISM PLUS trial was conducted at a time when the standard of care of managing acute coronary syndromes was different from that of present times in terms of oral platelet ADP receptor (P2Y12) antagonists use and the routine use of intracoronary stents.</p><p><em>ADVANCE study</em><br />The ADVANCE study determined the safety and efficacy of the tirofiban 25 microgram/kg dose bolus regimen as compared with placebo in patients undergoing elective or urgent PCI who exhibit high-risk characteristics including the presence of at least one coronary narrowing &ge;70% and diabetes, need for multi-vessel intervention, or NSTE-ACS. All patients received unfractionated heparin, acetylsalicylic acid (ASA) and a thienopyridine loading dose followed by maintenance therapy. A total of 202 patients were randomised to either tirofiban (25 microgram/kg bolus IV over 3 minutes followed by a continuous IV infusion of 0.15 microgram/kg/minute for 24-48 hours) or Placebo given immediately before PCI.</p><p>The primary endpoint was a composite of death, nonfatal MI, urgent target vessel revascularization (uTVR), or thrombotic bailout GP IIb/IIIa inhibitor therapy within a median follow-up of 180 days after the index procedure. The safety endpoints of major and minor bleeding were defined according to the TIMI criteria.</p><p>In the intent-to-treat population, the cumulative incidence of the primary end point was 35% and 20% in placebo and tirofiban groups, respectively (hazard ratio [HR] 0.51 [95% confidence interval (CI), 0.29 to 0.88]; p=0.01). As compared with placebo, there was a significant reduction in the composite of death, MI, or uTVR in the tirofiban group (31% vs. 20%, HR, 0.57 95% CI, 0.99&ndash;0.33]; p=0.048.</p><p><em>EVEREST study</em><br />The randomised open-label EVEREST trial compared the upstream 0.4 microgram/kg/min loading dose regimen initiated in the coronary care unit with the tirofiban 25 microgram/kg dose bolus regimen or abciximab 0.25 milligram/kg initiated 10 minutes prior to PCI. All patients additionally received ASA and a thienopyridine. The 93 enrolled NSTE-ACS patients underwent angiography and PCI as appropriate, within 24-48 hours of admission.</p><p>With respect to the primary endpoints of tissue level perfusion and troponin I release, the results of EVEREST determined significantly lower rates of post-PCI TMPG 0/1 (6.2% vs. 20% vs. 35.5%, respectively; p=0.015), and improved post-PCI MCE score index (0.88 &plusmn; 0.18 vs. 0.77 &plusmn; 0.32 vs. 0.71 &plusmn; 0.30, respectively; p&lt;0.05).</p><p>The incidence of post-procedural cardiac Troponin I (cTnI) elevation was significantly reduced in patients treated with the upstream tirofiban regimen compared with PCI 25 microgram/kg dose bolus tirofiban or abciximab (9.4% vs. 30% vs. 38.7%, respectively; p=0.018). The cTnI levels post-PCI were also significantly decreased with the upstream regimen of tirofiban compared with PCI tirofiban (3.8 &plusmn; 4.1 vs. 7.2 &plusmn; 12; p=0.015) and abciximab (3.8 &plusmn; 4.1 vs. 9 &plusmn; 13.8; p=0.0002). The comparison between the PCI tirofiban 25 microgram/kg dose bolus and abciximab regimens indicated no significant differences in the rate of TMPG 0/1 post-PCI (20% vs. 35%; p=NS).</p><p><em>On-TIME 2</em>&nbsp;study<br />The On-TIME 2 trial was a multi-centre, prospective, randomised, controlled clinical trial which was designed to assess the effect of early upfront tirofiban administration using the 25 microgram/kg dose bolus regimen in patients with STEMI planned for primary PCI. All patients received ASA, a 600 mg loading dose of clopidogrel, and unfractionated heparin. The use of bail-out tirofiban was allowed according to pre-specified criteria. The study was accomplished in two phases: a pilot, open label phase (n=414) followed by a larger double-blind phase (n=984). A pooled analysis of data from both phases was pre-specified to evaluate the effect of the 25 microgram/kg dose bolus regimen compared to control as measured by a primary endpoint defined as the 30-day MACE rate (death, recurrent MI and uTVR).</p><p>In this pooled analysis, MACE at 30 days was significantly reduced by early upfront initiation of tirofiban compared to control (5.8% vs. 8.6%; p=0.043). In addition, there was a strong trend toward a significant decrease in mortality with tirofiban with respect to all-cause death (2.2% in the tirofiban arm vs. 4.1% in the control arm; p=0.051). This mortality benefit was mainly due to a reduction of cardiac death (2.1% vs. 3.6%; p=0.086). At 1-year follow-up (the secondary endpoint), the mortality difference was maintained (3.7% vs. 5.8%; p=0.078 for all-cause mortality and 2.5% vs. 4.4% for cardiac mortality; p=0.061).</p><p>Patients who underwent primary PCI (86% of study population of pooled analysis) demonstrated a significant reduction in mortality both at 30 days (1.0% in the tirofiban group vs. 3.9% in the control group; p=0.001) and at 1 year (2.4% for tirofiban vs. 5.5% for control; p=0.007).</p><p><em>MULTISTRATEGY study</em><br />The MULTISTRATEGY study was an open-label, 2X2 factorial, multinational trial which compared the tirofiban (n=372) with abciximab (n=372) when used in conjunction with either a sirolimus-eluting (SES) or bare metal stent (BMS), in patients with STEMI. Either tirofiban (bolus of 25 microgram/kg, followed by an infusion at 0.15 microgram/kg/min continued for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg, followed by a 12-hour infusion at 0.125 microgram/kg/min) was initiated before arterial sheath insertion during the angiography. All patients received unfractionated heparin, ASA and clopidogrel.</p><p>The primary endpoint for the drug comparison was cumulative ST-segment resolution expressed as the proportion of patients who achieve at least 50% recovery within 90 minutes after the last balloon inflation and tested the hypothesis that tirofiban is noninferior to abciximab with respect to this endpoint.</p><p>In the intention-to-treat population, the percentage of patients with at least 50% recovery from ST-segment elevation was not significantly different between tirofiban (85.3%) and abciximab (83.6%), demonstrating the non-inferiority of tirofiban to abciximab (RR for tirofiban vs. abciximab, 1.020; 97.5% CI, 0.958-1.086; p&lt;0.001 for non-inferiority).</p><p>At 30 days, the rates of major adverse cardiac events (MACE) were similar for abciximab and tirofiban (4.3% vs. 4.0%, respectively; p=0.85) with these results maintained at 8 months (12.4% vs. 9.9%, respectively; p=0.30).</p><p>In On-TIME 2 and MULTISTRATEGY, patients were treated with dual oral antiplatelet therapy consisting of ASA and high-dose clopidogrel. The efficacy of tirofiban in combination with either prasugrel or ticagrelor has not been established in randomised controlled trials.</p><p><em>Meta-analysis of Randomised Trials of tirofiban 25 microgram/kg Dose Bolus Regimen</em><br />The results of a meta-analysis evaluating the efficacy of the tirofiban 25 microgram/kg dose bolus regimen versus abciximab (including 2213 ACS patients, across the ACS spectrum, with both NSTEMI and STEMI patients) did not reveal any significant difference in the OR for death or MI at 30 days between the two agents (OR, 0.87 [0.56-1.35]; p=0.54). Similarly, there were no significant differences in 30-day mortality between tirofiban and abciximab (OR, 0.73 [0.36-1.47]; p=0.38). Additionally, at the longest follow-up, death or MI was not significantly different between tirofiban and abciximab (OR, 0.84 [0.59-1.21]; p=0.35).</p><p><em>TARGETstudy</em><br />In one study using a 10 microgram/kg bolus followed by a 0.15 microgram/kg/min infusion of tirofiban, tirofiban failed to demonstrate noninferiority to abciximab: the incidence of the composite primary endpoint (death, MI, or uTVR at 30 days) showed that abciximab was significantly more effective on clinically relevant endpoints, with 7.6% in the tirofiban and 6.0% in the abciximab group (p=0.038), which was mainly due to a significant increase in the incidence of MI at 30 days (respectively 6.9% vs. 5.4%; p=0.04).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Distribution</strong><br />Tirofiban is not strongly bound to plasma protein, and protein binding is concentration-independent in the range of 0.01&ndash;25 microgram/ml. The unbound fraction in human plasma is 35%.</p><p>The distribution volume of tirofiban in the steady state is about 30 litres.</p><p><strong>Biotransformation</strong><br />Experiments with&nbsp;<sup>14</sup>C-labelled tirofiban showed the radioactivity in urine and faeces to be emitted chiefly by unchanged tirofiban. The radioactivity in circulating plasma originates mainly from unchanged tirofiban (up to 10 hours after administration). These data suggested limited metabolisation of tirofiban.</p><p><strong>Elimination</strong><br />After intravenous administration of&nbsp;<sup>14</sup>C-labelled tirofiban to healthy subjects, 66% of the radioactivity was recovered in the urine, 23% in the faeces. The total recovery of radioactivity was 91%. Renal and biliary excretion contribute significantly to the elimination of tirofiban.</p><p>In healthy subjects the plasma clearance of tirofiban is about 250 ml/min. Renal clearance is 39&ndash;69% of plasma clearance. The half-life is about 1.5 hours.</p><p><strong>Gender</strong><br />The plasma clearance of tirofiban in patients with coronary heart disease is similar in men and women.</p><p><strong>Elderly patients</strong><br />The plasma clearance of tirofiban is about 25% less in elderly (&gt;65 years) patients with coronary heart disease in comparison to younger (&le;65 years) patients.</p><p><strong>Ethnic groups</strong><br />No difference was found in the plasma clearance between patients of different ethnic groups.</p><p><strong>Coronary Artery Disease</strong><br />In patients with unstable angina pectoris or NQWMI the plasma clearance was about 200 ml/min, the renal clearance 39% of the plasma clearance. The half-life is about two hours.</p><p><strong>Impaired renal function</strong><br />In clinical studies, patients with decreased renal function showed a reduced plasma clearance of tirofiban depending on the degree of impairment of creatinine clearance. In patients with a creatinine clearance of less than 30 ml/min, including haemodialysis patients, the plasma clearance of tirofiban is reduced to a clinically relevant extent (over 50%) (see section 4.2)<em>.</em>&nbsp;Tirofiban is removed by haemodialysis.</p><p><strong>Liver failure</strong><br />There is no evidence of a clinically significant reduction of the plasma clearance of tirofiban in patients with mild to moderate liver failure. No data are available on patients with severe liver failure.</p><p><strong>Effects of other drugs</strong><br />The plasma clearance of tirofiban in patients receiving one of the following drugs was compared to that in patients not receiving that drug in a sub-set of patients (n=762) in the PRISM study. There were no substantial (&gt;15%) effects of these drugs on the plasma clearance of tirofiban: acebutolol, alprazolam, amlodipine, aspirin preparations, atenolol, bromazepam, captopril, diazepam, digoxin, diltiazem, docusate sodium, enalapril, furosemide, glibenclamide, unfractionated heparin, insulin, isosorbide, lorazepam, lovastatin, metoclopramide, metoprolol, morphine, nifedipine, nitrate preparations, oxazepam, paracetamol, potassium chloride, propranolol, ranitidine, simvastatin, sucralfate and temazepam.</p><p>The pharmacokinetics and pharmacodynamics of tirofiban were investigated when concomitantly administered with enoxaparin (1 milligram/kg subcutaneously every 12 hours) and compared with the combination of tirofiban and unfractionated heparin. There was no difference in the clearance of tirofiban between the two groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>Fertility and reproductive performance were not affected in studies with male and female rats given intravenous doses of tirofiban hydrochloride up to 5 mg/kg/day. These dosages are approximately 22-fold higher than the maximum recommended daily dose in humans.</p><p>However, animal studies are insufficient to draw conclusions with respect to reproductive toxicity in humans.</p><p>Tirofiban crosses the placenta in rats and rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Sodium chloride</li><li>Sodium citrate</li><li>Citric acid</li><li>Sodium hydroxide/hydrochloric acid</li><li>Water for injection.&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatibility has been found with diazepam. Therefore, Fibrosta and diazepam should not be administered in the same intravenous line.</p><p>No incompatibilities have been found with Fibrosta and the following intravenous formulations: atropine sulfate, dobutamine, dopamine, epinephrine HCl, furosemide, heparin, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride, propanolol HCl and famotidine injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

From a microbiological point of view the diluted solution for infusion should be used immediately. If not used immediately, in use storage conditions are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>50 ml type I clear glass vials with grey bromo-butyl rubber stoppers and orange aluminium flip-off caps.</p><p>Pack size: 1 Vial (50 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fibrosta concentrate for solution for infusion must be diluted before use.</p><p>See section 4.2.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 November 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>